On June 17, 2024, HOOKIPA Pharma Inc. conducted its 2024 Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders approved an amendment to increase the authorized shares of common stock from 200 million to 400 million. Additionally, Timothy Reilly, Ph.D., and Malte Peters were elected as Class II directors for a three-year term. The selection of PwC Wirtschaftsprüfung GmbH as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. Furthermore, an amendment for a potential reverse stock split in the range of 1-for-2 to 1-for-10, to be determined by the board of directors before June 17, 2025, was authorized. The meeting saw a quorum present with detailed voting results for each proposal provided. The Certificate of Amendment was filed with the Secretary of State of Delaware on June 18, 2024, and is effective from that date.

On June 17, 2024, HOOKIPA Pharma Inc. conducted its 2024 Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders approved an amendment to increase the authorized shares of common stock from 200 million to 400 million. Additionally, Timothy Reilly, Ph.D., and Malte Peters were elected as Class II directors for a three-year term. The selection of PwC Wirtschaftsprüfung GmbH as the independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified. Furthermore, an amendment for a potential reverse stock split in the range of 1-for-2 to 1-for-10, to be determined by the board of directors before June 17, 2025, was authorized. The meeting saw a quorum present with detailed voting results for each proposal provided. The Certificate of Amendment was filed with the Secretary of State of Delaware on June 18, 2024, and is effective from that date.